Abstract Body

African studies demonstrate that genital inflammation decreases tenofovir (TFV) gel’s efficacy. We evaluated the impact of inflammation and dysbiosis on cervicovaginal fluid (CVF) TFV concentrations in US women taking oral TDF/FTC for PrEP.

Southern Californian women on oral TDF/FTC in the Adherence Enhancement Guided by Individualized Texting and Drug Levels (AEGiS) study had CVF collected at week 24 to evaluate (i) sexually transmitted bacterial (gonorrhea, chlamydia, gardnerella and trichomonas), viral (HPV, CMV and HSV-1/2) and fungal (Candida) infections, (ii) microbiome composition by 16S sequencing (V3-V4 region) and (iii) cytokine profiles by ELISA (IL-8, MIP-1a, MIP-1b, and IP-10). Microbiome Community State Types (CSTs) were assigned based on described characteristics (i.e. CST I, II, III, V dominated by lactobacilli and CST IV containing mostly non-lactobacilli species). TFV in CVF and tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) were also measured at week 24. CVF TFV of 100-1000ng/mL benchmarked typical genital concentrations; DBS TVF-DP ≥700fmol/punch suggested long-term adherence. Univariate statistical analysis was used to determine factors associated with low and high CVF TFV.  

34 women had CVF specimens collected at week 24. Median age was 43 (IQR 35-47) years. 15% (5/34) had discordant tenofovir concentrations (i.e. DBS TFV-DP≥700 and CVF TFV<100). No inflammatory process was associated with lower CVF TFV concentrations or tenofovir discordance. Notably, among the 26 participants assessed for vaginitis (Candida, Gardnerella or Trichomonas), women with possible vaginitis (n=13) were more likely to have high (>1000 ng/mL) CVF TFV concentrations compared to those without vaginitis (77% versus 31%, p<0.05). No difference was seen in CVF TFV concentrations by vaginal microbiome type. 3 of the 5 women with discordance had non-lactobacillus dominant microbiomes; however, they were dominated by non-vaginitis organisms (2 E. cloacae, 1 E. coli).

Presence of genital viruses, cytokines or Gardnerella spp. were not associated with low CVF TFV levels in women taking oral PrEP. Women with vaginitis may actually have higher CVF TFV levels, perhaps due to inflammatory processes augmenting blood flow and TFV penetration into the vaginal compartment.